omega-3脂肪酸对2型糖尿病的影响:一项系统综述和荟萃分析

IF 3 Prostaglandins, leukotrienes, and essential fatty acids Pub Date : 2022-07-01 DOI:10.1016/j.plefa.2022.102456

Yanan Xiao , Qifang Zhang , Xueling Liao , Ulf Elbelt , Karsten H. Weylandt

{"title":"omega-3脂肪酸对2型糖尿病的影响:一项系统综述和荟萃分析","authors":"Yanan Xiao , Qifang Zhang , Xueling Liao , Ulf Elbelt , Karsten H. Weylandt","doi":"10.1016/j.plefa.2022.102456","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>: The effect of omega-3 polyunsaturated fatty acids (n-3 PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on cardiovascular risk modification in type 2 diabetes and related complications remain unclear. We aim to assess the published effects of n-3 PUFA interventions on lipid risk factors in type 2 diabetes.</p></div><div><h3>Methods</h3><p>: We searched the literature on Pubmed, Embase, CENTRAL, and Web of Science databases in order to perform a pooled analysis of randomized clinical trials (RCTs) assessing n-3 PUFA interventions in type 2 diabetes. The primary outcomes analyzed were the effect of n -3 PUFAs on metabolic biomarkers in type 2 diabetes.</p></div><div><h3>Results</h3><p>: 46 RCTs involving 4991 patients with type 2 diabetes were identified for further analysis. Analysis of results showed that n-3 PUFAs interventions significantly improved total cholesterol (TC, WMD = -0.22; 95% CI: -0.32∼ -0.11), triglyceride (TG,WMD = -0.36; 95% CI: -0.48∼-0.25), high-density lipoprotein cholesterol (HDL-C,WMD = 0.05; 95% CI: 0.02∼ 0.08), hemoglobin A1c (HbA1c, WMD = -0.19; 95% CI: -0.31∼-0.06) and C-reactive protein (CRP,WMD = -0.40; 95% CI: -0.74∼-0.07) levels compared to controls (<em>p</em> < 0.05). There was no significant effect on renal function, fasting blood sugar (FBS), insulin resistance (HOMA-IR), low-density lipoprotein cholesterol (LDL-C), adiponectin and leptin (<em>p</em> > 0.05).</p></div><div><h3>Conclusions</h3><p>: The results of this systematic review suggest that n-3 PUFAs can improve cardiovascular risk factors in type 2 diabetes.</p></div>","PeriodicalId":94179,"journal":{"name":"Prostaglandins, leukotrienes, and essential fatty acids","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"The effects of omega-3 fatty acids in type 2 diabetes: A systematic review and meta-analysis\",\"authors\":\"Yanan Xiao , Qifang Zhang , Xueling Liao , Ulf Elbelt , Karsten H. Weylandt\",\"doi\":\"10.1016/j.plefa.2022.102456\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>: The effect of omega-3 polyunsaturated fatty acids (n-3 PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on cardiovascular risk modification in type 2 diabetes and related complications remain unclear. We aim to assess the published effects of n-3 PUFA interventions on lipid risk factors in type 2 diabetes.</p></div><div><h3>Methods</h3><p>: We searched the literature on Pubmed, Embase, CENTRAL, and Web of Science databases in order to perform a pooled analysis of randomized clinical trials (RCTs) assessing n-3 PUFA interventions in type 2 diabetes. The primary outcomes analyzed were the effect of n -3 PUFAs on metabolic biomarkers in type 2 diabetes.</p></div><div><h3>Results</h3><p>: 46 RCTs involving 4991 patients with type 2 diabetes were identified for further analysis. Analysis of results showed that n-3 PUFAs interventions significantly improved total cholesterol (TC, WMD = -0.22; 95% CI: -0.32∼ -0.11), triglyceride (TG,WMD = -0.36; 95% CI: -0.48∼-0.25), high-density lipoprotein cholesterol (HDL-C,WMD = 0.05; 95% CI: 0.02∼ 0.08), hemoglobin A1c (HbA1c, WMD = -0.19; 95% CI: -0.31∼-0.06) and C-reactive protein (CRP,WMD = -0.40; 95% CI: -0.74∼-0.07) levels compared to controls (<em>p</em> < 0.05). There was no significant effect on renal function, fasting blood sugar (FBS), insulin resistance (HOMA-IR), low-density lipoprotein cholesterol (LDL-C), adiponectin and leptin (<em>p</em> > 0.05).</p></div><div><h3>Conclusions</h3><p>: The results of this systematic review suggest that n-3 PUFAs can improve cardiovascular risk factors in type 2 diabetes.</p></div>\",\"PeriodicalId\":94179,\"journal\":{\"name\":\"Prostaglandins, leukotrienes, and essential fatty acids\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostaglandins, leukotrienes, and essential fatty acids\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0952327822000680\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins, leukotrienes, and essential fatty acids","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952327822000680","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 12

摘要

背景:omega-3多不饱和脂肪酸(n-3 PUFAs)，如二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)对2型糖尿病心血管风险改变及相关并发症的影响尚不清楚。我们的目的是评估已发表的n-3 PUFA干预对2型糖尿病脂质危险因素的影响。方法:我们检索了Pubmed、Embase、CENTRAL和Web of Science数据库的文献，对评估n-3 PUFA干预2型糖尿病的随机临床试验(rct)进行了合并分析。分析的主要结局是n -3 PUFAs对2型糖尿病代谢生物标志物的影响。结果:纳入46项随机对照试验，涉及4991例2型糖尿病患者，以供进一步分析。结果分析显示，n-3 PUFAs干预可显著改善总胆固醇(TC, WMD = -0.22;95%置信区间:-0.32∼-0.11)、甘油三酯(TG,大规模杀伤性武器= -0.36;95% CI: -0.48 ~ -0.25)，高密度脂蛋白胆固醇(HDL-C,WMD = 0.05;95% CI: 0.02 ~ 0.08)，血红蛋白A1c (HbA1c, WMD = -0.19;95% CI: -0.31 ~ -0.06)和c反应蛋白(CRP,WMD = -0.40;与对照组相比，95% CI: -0.74 ~ -0.07)水平(p <0.05)。对肾功能、空腹血糖(FBS)、胰岛素抵抗(HOMA-IR)、低密度脂蛋白胆固醇(LDL-C)、脂联素和瘦素(p >0.05)。结论:本系统综述的结果表明，n-3 PUFAs可以改善2型糖尿病的心血管危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The effects of omega-3 fatty acids in type 2 diabetes: A systematic review and meta-analysis

Background

: The effect of omega-3 polyunsaturated fatty acids (n-3 PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on cardiovascular risk modification in type 2 diabetes and related complications remain unclear. We aim to assess the published effects of n-3 PUFA interventions on lipid risk factors in type 2 diabetes.

Methods

: We searched the literature on Pubmed, Embase, CENTRAL, and Web of Science databases in order to perform a pooled analysis of randomized clinical trials (RCTs) assessing n-3 PUFA interventions in type 2 diabetes. The primary outcomes analyzed were the effect of n -3 PUFAs on metabolic biomarkers in type 2 diabetes.

Results

: 46 RCTs involving 4991 patients with type 2 diabetes were identified for further analysis. Analysis of results showed that n-3 PUFAs interventions significantly improved total cholesterol (TC, WMD = -0.22; 95% CI: -0.32∼ -0.11), triglyceride (TG,WMD = -0.36; 95% CI: -0.48∼-0.25), high-density lipoprotein cholesterol (HDL-C,WMD = 0.05; 95% CI: 0.02∼ 0.08), hemoglobin A1c (HbA1c, WMD = -0.19; 95% CI: -0.31∼-0.06) and C-reactive protein (CRP,WMD = -0.40; 95% CI: -0.74∼-0.07) levels compared to controls (p < 0.05). There was no significant effect on renal function, fasting blood sugar (FBS), insulin resistance (HOMA-IR), low-density lipoprotein cholesterol (LDL-C), adiponectin and leptin (p > 0.05).